320 related articles for article (PubMed ID: 21525157)
1. Effects of risedronate and low-dose transdermal testosterone on bone mineral density in women with anorexia nervosa: a randomized, placebo-controlled study.
Miller KK; Meenaghan E; Lawson EA; Misra M; Gleysteen S; Schoenfeld D; Herzog D; Klibanski A
J Clin Endocrinol Metab; 2011 Jul; 96(7):2081-8. PubMed ID: 21525157
[TBL] [Abstract][Full Text] [Related]
2. Sequential Therapy With Recombinant Human IGF-1 Followed by Risedronate Increases Spine Bone Mineral Density in Women With Anorexia Nervosa: A Randomized, Placebo-Controlled Trial.
Haines MS; Kimball A; Meenaghan E; Bachmann KN; Santoso K; Eddy KT; Singhal V; Ebrahimi S; Dechant E; Weigel T; Ciotti L; Keane RJ; Gleysteen S; Mickley D; Bredella MA; Tan CO; Gupta R; Misra M; Schoenfeld D; Klibanski A; Miller KK
J Bone Miner Res; 2021 Nov; 36(11):2116-2126. PubMed ID: 34355814
[TBL] [Abstract][Full Text] [Related]
3. Risedronate for prevention of bone mineral density loss in patients receiving high-dose glucocorticoids: a randomized double-blind placebo-controlled trial.
Mok CC; Tong KH; To CH; Siu YP; Ma KM
Osteoporos Int; 2008 Mar; 19(3):357-64. PubMed ID: 18038273
[TBL] [Abstract][Full Text] [Related]
4. Changes in bone mineral density at 3 years in postmenopausal women receiving anastrozole and risedronate in the IBIS-II bone substudy: an international, double-blind, randomised, placebo-controlled trial.
Sestak I; Singh S; Cuzick J; Blake GM; Patel R; Gossiel F; Coleman R; Dowsett M; Forbes JF; Howell A; Eastell R
Lancet Oncol; 2014 Dec; 15(13):1460-1468. PubMed ID: 25456365
[TBL] [Abstract][Full Text] [Related]
5. Risedronate prevents bone loss in breast cancer survivors: a 2-year, randomized, double-blind, placebo-controlled clinical trial.
Greenspan SL; Brufsky A; Lembersky BC; Bhattacharya R; Vujevich KT; Perera S; Sereika SM; Vogel VG
J Clin Oncol; 2008 Jun; 26(16):2644-52. PubMed ID: 18427147
[TBL] [Abstract][Full Text] [Related]
6. Denosumab increases spine bone density in women with anorexia nervosa: a randomized clinical trial.
Haines MS; Kimball A; Meenaghan E; Santoso K; Colling C; Singhal V; Ebrahimi S; Gleysteen S; Schneider M; Ciotti L; Belfer P; Eddy KT; Misra M; Miller KK
Eur J Endocrinol; 2022 Nov; 187(5):697-708. PubMed ID: 36134902
[TBL] [Abstract][Full Text] [Related]
7. Once-weekly risedronate in men with osteoporosis: results of a 2-year, placebo-controlled, double-blind, multicenter study.
Boonen S; Orwoll ES; Wenderoth D; Stoner KJ; Eusebio R; Delmas PD
J Bone Miner Res; 2009 Apr; 24(4):719-25. PubMed ID: 19049326
[TBL] [Abstract][Full Text] [Related]
8. Randomized, double-blinded, placebo-controlled, trial of risedronate for the prevention of bone mineral density loss in nonmetastatic prostate cancer patients receiving radiation therapy plus androgen deprivation therapy.
Choo R; Lukka H; Cheung P; Corbett T; Briones-Urbina R; Vieth R; Ehrlich L; Kiss A; Danjoux C
Int J Radiat Oncol Biol Phys; 2013 Apr; 85(5):1239-45. PubMed ID: 23265571
[TBL] [Abstract][Full Text] [Related]
9. Teriparatide increases bone formation and bone mineral density in adult women with anorexia nervosa.
Fazeli PK; Wang IS; Miller KK; Herzog DB; Misra M; Lee H; Finkelstein JS; Bouxsein ML; Klibanski A
J Clin Endocrinol Metab; 2014 Apr; 99(4):1322-9. PubMed ID: 24456286
[TBL] [Abstract][Full Text] [Related]
10. The effect of weekly risedronate on periprosthetic bone resorption following total hip arthroplasty: a randomized, double-blind, placebo-controlled trial.
Sköldenberg OG; Salemyr MO; Bodén HS; Ahl TE; Adolphson PY
J Bone Joint Surg Am; 2011 Oct; 93(20):1857-64. PubMed ID: 22012522
[TBL] [Abstract][Full Text] [Related]
11. Phase III randomized, placebo-controlled, double-blind trial of risedronate for the prevention of bone loss in premenopausal women undergoing chemotherapy for primary breast cancer.
Hines SL; Mincey BA; Sloan JA; Thomas SP; Chottiner E; Loprinzi CL; Carlson MD; Atherton PJ; Salim M; Perez EA
J Clin Oncol; 2009 Mar; 27(7):1047-53. PubMed ID: 19075260
[TBL] [Abstract][Full Text] [Related]
12. Risedronate improves bone mineral density in Crohn's disease: a two year randomized controlled clinical trial.
Soo I; Siffledeen J; Siminoski K; McQueen B; Fedorak RN
J Crohns Colitis; 2012 Aug; 6(7):777-86. PubMed ID: 22398088
[TBL] [Abstract][Full Text] [Related]
13. Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy.
Wallach S; Cohen S; Reid DM; Hughes RA; Hosking DJ; Laan RF; Doherty SM; Maricic M; Rosen C; Brown J; Barton I; Chines AA
Calcif Tissue Int; 2000 Oct; 67(4):277-85. PubMed ID: 11000340
[TBL] [Abstract][Full Text] [Related]
14. Risedronate in adults with osteogenesis imperfecta type I: increased bone mineral density and decreased bone turnover, but high fracture rate persists.
Bradbury LA; Barlow S; Geoghegan F; Hannon RA; Stuckey SL; Wass JA; Russell RG; Brown MA; Duncan EL
Osteoporos Int; 2012 Jan; 23(1):285-94. PubMed ID: 21739105
[TBL] [Abstract][Full Text] [Related]
15. Post hoc analysis of a single IV infusion of zoledronic acid versus daily oral risedronate on lumbar spine bone mineral density in different subgroups with glucocorticoid-induced osteoporosis.
Roux C; Reid DM; Devogelaer JP; Saag K; Lau CS; Reginster JY; Papanastasiou P; Bucci-Rechtweg C; Su G; Sambrook PN
Osteoporos Int; 2012 Mar; 23(3):1083-90. PubMed ID: 21975559
[TBL] [Abstract][Full Text] [Related]
16. Bone mineral density in young women with primary ovarian insufficiency: results of a three-year randomized controlled trial of physiological transdermal estradiol and testosterone replacement.
Popat VB; Calis KA; Kalantaridou SN; Vanderhoof VH; Koziol D; Troendle JF; Reynolds JC; Nelson LM
J Clin Endocrinol Metab; 2014 Sep; 99(9):3418-26. PubMed ID: 24905063
[TBL] [Abstract][Full Text] [Related]
17. Risedronate and ergocalciferol prevent hip fracture in elderly men with Parkinson disease.
Sato Y; Honda Y; Iwamoto J
Neurology; 2007 Mar; 68(12):911-5. PubMed ID: 17372126
[TBL] [Abstract][Full Text] [Related]
18. Determinants of skeletal loss and recovery in anorexia nervosa.
Miller KK; Lee EE; Lawson EA; Misra M; Minihan J; Grinspoon SK; Gleysteen S; Mickley D; Herzog D; Klibanski A
J Clin Endocrinol Metab; 2006 Aug; 91(8):2931-7. PubMed ID: 16735492
[TBL] [Abstract][Full Text] [Related]
19. Combination therapy with risedronate and teriparatide in male osteoporosis.
Walker MD; Cusano NE; Sliney J; Romano M; Zhang C; McMahon DJ; Bilezikian JP
Endocrine; 2013 Aug; 44(1):237-46. PubMed ID: 23099796
[TBL] [Abstract][Full Text] [Related]
20. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group.
Harris ST; Watts NB; Genant HK; McKeever CD; Hangartner T; Keller M; Chesnut CH; Brown J; Eriksen EF; Hoseyni MS; Axelrod DW; Miller PD
JAMA; 1999 Oct; 282(14):1344-52. PubMed ID: 10527181
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
